Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Have A Look At William Blair's Top Biotech Picks For 2023
06:32pm, Sunday, 25'th Dec 2022 Benzinga
William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.
Seagen Inc.'s (NASD
Despite Neurocrine's Epilepsy Drug Missing Primary Goal In Pediatric Trial, Analyst Sees Strong Growth
01:00pm, Wednesday, 07'th Dec 2022 Benzinga
Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104 did not meet its primary endpoint in the Phase 2 STEAMBOAT study compared to placebo in pediatric patients with epileptic encephalopathy with
Oil Firm Eyeing 3,755% Q4 Growth Leads 24 Fastest-Growing Stocks
02:58pm, Thursday, 01'st Dec 2022
With analysts expecting a whopping 3,755% Q4 growth, H.F. Sinclair leads this list of 24 of today's fastest-growing stocks.
Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases
02:10pm, Friday, 25'th Nov 2022
Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
01:21pm, Monday, 14'th Nov 2022 Benzinga
BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the stock. Gain Therapeutics shares rose 1.3% to close at $
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
03:00am, Friday, 11'th Nov 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday's high of $125.99. It is forming a bullish channel.
Three Stocks Rise, Watchlist Grows With Midterm Elections, Fed In Focus
05:32pm, Monday, 07'th Nov 2022
As Leaderboard stocks Enphase Energy, Wingstop and Cheniere Energy navigate Fed rate hikes, all eyes now turn to the midterm elections. The post Three Stocks Rise, Watchlist Grows With Midterm Electio
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
02:19pm, Friday, 04'th Nov 2022
Neurocrine (NBIX) could produce exceptional returns because of its solid growth attributes.
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
05:34pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
12:45pm, Tuesday, 01'st Nov 2022 Zacks Investment Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences, Inc. (NBIX) Q3 2022 Earnings Call Transcript
12:13pm, Tuesday, 01'st Nov 2022
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2022 Earnings Conference Call November 1, 2022 8:00 AM ET Company Participants Todd Tushla - VP of IR Kevin Gorman - CEO Matt Abernethy - CFO Eric Benevi
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
09:47am, Tuesday, 01'st Nov 2022
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.86% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Blazing Hot Neurocrine Biosciences, With 35% Run This Year, Extends Breakout On Quarterly Beat
09:19am, Tuesday, 01'st Nov 2022
Neurocrine Biosciences beat third-quarter forecasts and raised its Ingrezza outlook for 2022, leading NBIX stock to jump Tuesday. The post Blazing Hot Neurocrine Biosciences, With 35% Run This Year, E
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
02:01pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
02:01pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
